QURT
Quarta-Rad, Inc.0.6500
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
10.33MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
Q3 FY2025 results
Quarta-Rad posted Q3 sales of $62.5K, up 234% y/y from $18.7K yet down from Q2's $100K (derived), driven by Sellavir's related-party services at $60K while Quarta-Rad device sales fell 72% y/y to $2.5K amid supply constraints. Gross profit hit $28.8K but operating loss widened to $66.0K from stock-based comp of $55.7K, pushing net loss to $66.6K versus $2.6K last year; YTD net loss reached $216.1K on $162.7K revenue, up 133% y/y. Cash dropped to $33K after $29.9K ops burn YTD, with $109K equity and heavy related-party notes. No debt or FCF disclosed. CenterEye faces market acceptance risk.
10-Q
Q2 FY2025 results
Quarta-Rad's Q2 FY2025 revenue climbed 132% y/y to $67.3K, driven by Sellavir's $65K in AI consulting services to related parties, while Quarta-Rad's device sales dropped 92% y/y to $2.3K amid supply constraints from the Russian invasion of Ukraine. Gross profit rose to $37.7K, but operating expenses jumped 47% y/y to $124.3K, fueled by $55.7K in stock-based compensation, yielding an operating loss of $86.6K—up 17% y/y—versus a net loss of $72.1K after $13.7K foreign currency gains. YTD revenue doubled 96% y/y to $100.2K, narrowing net loss to $149.5K from $154K, with diluted EPS steady at $(0.01) on 15.9M shares. Cash dwindled to $29.6K after $33.5K operating outflow, no debt but $250K liabilities mostly related-party payables; a $199K note receivable transfer settled obligations. Sellavir's CenterEye AI platform shows early Japan traction. Yet competition in AI call center software poses adoption risks.
10-Q
Q1 FY2025 results
Quarta-Rad posted Q1 FY2025 net sales of $32.9K, up 49.2% y/y from $22.0K, driven by $30.0K from Sellavir's AI services while Quarta-Rad's device sales fell 86.9% y/y to $2.9K amid supply constraints. Gross loss narrowed to $1.4K from $11.8K profit, with operating loss widening to $89.9K (up 43.8% y/y) on $37.1K stock-based compensation, yet net loss improved 15.5% y/y to $77.4K, or $0.00 per diluted share on 15.8M shares. Cash dipped q/q to $49.8K after $13.3K operating outflow, with no capex so free cash flow matched; related-party notes receivable stand at $403.5K, but a $382K working capital deficit persists. Sellavir's CenterEye platform gained Japan traction. Geopolitical risks from the Russian invasion of Ukraine continue to crimp device inventory.
IPO
Website
Sector
Industry
ARAY
Accuray Incorporated
1.02-0.03
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
IRMD
iRadimed Corporation
96.87-0.15
MIR
Mirion Technologies, Inc.
24.15-0.17
QDEL
QuidelOrtho Corporation
28.88-0.18
QTIH
QT Imaging Holdings, Inc.
6.10-0.02
QTRX
Quanterix Corporation
7.36-0.05
SRTS
Sensus Healthcare, Inc.
3.80+0.11
TDY
Teledyne Technologies Incorpora
506.54-7.75
UCLE
US Nuclear Corp.
0.04-0.06